160 related articles for article (PubMed ID: 19797313)
21. PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.
Wang D; Li Y; Wu C; Liu Y
PLoS One; 2011 Feb; 6(2):e17048. PubMed ID: 21390327
[TBL] [Abstract][Full Text] [Related]
22. Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report.
Alge JL; Wenderfer SE; Hicks J; Bekheirnia MR; Schady DA; Kain JS; Braun MC
BMC Nephrol; 2017 Jul; 18(1):243. PubMed ID: 28720077
[TBL] [Abstract][Full Text] [Related]
23. Embryonal hyperplasia of Bowman's capsular epithelium in patients with WT1 mutations.
Fukuzawa R; Eccles MR; Ikeda M; Hata J
Pediatr Nephrol; 2003 Jan; 18(1):9-13. PubMed ID: 12488983
[TBL] [Abstract][Full Text] [Related]
24. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
[TBL] [Abstract][Full Text] [Related]
25. Genome-Wide Analysis of Wilms' Tumor 1-Controlled Gene Expression in Podocytes Reveals Key Regulatory Mechanisms.
Kann M; Ettou S; Jung YL; Lenz MO; Taglienti ME; Park PJ; Schermer B; Benzing T; Kreidberg JA
J Am Soc Nephrol; 2015 Sep; 26(9):2097-104. PubMed ID: 25636411
[TBL] [Abstract][Full Text] [Related]
26. Effects on kidney disease, fertility and development in mice inheriting a protein-truncating Denys-Drash syndrome allele (Wt1tmT396).
Patek CE; Brownstein DG; Fleming S; Wroe C; Rose L; Webb A; Berry RL; Devenney PS; Walker M; Maddocks OD; Lawrence NJ; Harrison DJ; Wood KM; Miles CG; Hooper ML
Transgenic Res; 2008 Jun; 17(3):459-75. PubMed ID: 18040647
[TBL] [Abstract][Full Text] [Related]
27. The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome.
Gao F; Maiti S; Sun G; Ordonez NG; Udtha M; Deng JM; Behringer RR; Huff V
Mol Cell Biol; 2004 Nov; 24(22):9899-910. PubMed ID: 15509792
[TBL] [Abstract][Full Text] [Related]
28. Podocytes degrade endocytosed albumin primarily in lysosomes.
Carson JM; Okamura K; Wakashin H; McFann K; Dobrinskikh E; Kopp JB; Blaine J
PLoS One; 2014; 9(6):e99771. PubMed ID: 24924335
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-466o-3p mediates β-catenin-induced podocyte injury by targeting Wilms tumor 1.
Chen Q; Chen J; Wang C; Chen X; Liu J; Zhou L; Liu Y
FASEB J; 2020 Nov; 34(11):14424-14439. PubMed ID: 32888352
[TBL] [Abstract][Full Text] [Related]
30. CMIP interacts with WT1 and targets it on the proteasome degradation pathway.
Zhang SY; Fan Q; Moktefi A; Ory V; Audard V; Pawlak A; Ollero M; Sahali D; Henique C
Clin Transl Med; 2021 Jul; 11(7):e460. PubMed ID: 34323419
[TBL] [Abstract][Full Text] [Related]
31. A novel WT1 gene mutation in a chinese girl with denys-drash syndrome.
Wang F; Cai J; Wang J; He M; Mao J; Zhu K; Zhao M; Guan Z; Li L; Jin H; Shu Q
J Clin Lab Anal; 2021 May; 35(5):e23769. PubMed ID: 33942367
[TBL] [Abstract][Full Text] [Related]
32. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter.
Lee TH; Pelletier J
Physiol Genomics; 2001 Dec; 7(2):187-200. PubMed ID: 11773605
[TBL] [Abstract][Full Text] [Related]
33. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
34. Alternatively spliced isoforms of WT1 control podocyte-specific gene expression.
Lefebvre J; Clarkson M; Massa F; Bradford ST; Charlet A; Buske F; Lacas-Gervais S; Schulz H; Gimpel C; Hata Y; Schaefer F; Schedl A
Kidney Int; 2015 Aug; 88(2):321-31. PubMed ID: 25993318
[TBL] [Abstract][Full Text] [Related]
35. WT1 Haploinsufficiency Supports Milder Renal Manifestation in Two Patients with Denys-Drash Syndrome.
Guaragna MS; Ribeiro de Andrade JG; de Freitas Carli B; Belangero VM; Maciel-Guerra AT; Guerra-Júnior G; de Mello MP
Sex Dev; 2017; 11(1):34-39. PubMed ID: 28081536
[TBL] [Abstract][Full Text] [Related]
36. Denys-Drash syndrome associated WT1 glutamine 369 mutants have altered sequence-preferences and altered responses to epigenetic modifications.
Hashimoto H; Zhang X; Zheng Y; Wilson GG; Cheng X
Nucleic Acids Res; 2016 Dec; 44(21):10165-10176. PubMed ID: 27596598
[TBL] [Abstract][Full Text] [Related]
37. Clinical pictures and novel mutations of WT1-associated Denys-Drash syndrome in two Chinese children.
Yue Z; Pei Y; Sun L; Huang W; Huang H; Hu B; Yang J; Jiang X; Mo Y; Chen S; Lai KN; Wang Y
Ren Fail; 2011; 33(9):910-4. PubMed ID: 21851196
[TBL] [Abstract][Full Text] [Related]
38. Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations.
Menendez-Castro C; Hilgers KF; Amann K; Daniel C; Cordasic N; Wachtveitl R; Fahlbusch F; Plank C; Dötsch J; Rascher W; Hartner A
Nephrol Dial Transplant; 2013 Jun; 28(6):1407-17. PubMed ID: 23229934
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic transcriptional reprogramming by WT1 mediates a repair response during podocyte injury.
Ettou S; Jung YL; Miyoshi T; Jain D; Hiratsuka K; Schumacher V; Taglienti ME; Morizane R; Park PJ; Kreidberg JA
Sci Adv; 2020 Jul; 6(30):eabb5460. PubMed ID: 32754639
[TBL] [Abstract][Full Text] [Related]
40. Role for first zinc finger of WT1 in DNA sequence specificity: Denys-Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites.
Wang D; Horton JR; Zheng Y; Blumenthal RM; Zhang X; Cheng X
Nucleic Acids Res; 2018 May; 46(8):3864-3877. PubMed ID: 29294058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
